Psylin News

Psylin Neurosciences, Amylin’s Pysch-Drug Offspring, Nearing First Clinical Trial

April 27, 2009 — There are still great voids in understanding the effects of even approved psychiatric drugs. But there’s no doubt that the business of selling antidepressants and the like can be extremely lucrative. Psylin Neurosciences—a joint venture of San Diego-based Amylin Pharmaceuticals and New York drug research firm PsychoGenics—is very much a product of both of those realities.
Download PDF >

Pyslin Commences Development of Compound for Depression

April 20, 2009 — Psylin Neurosciences Inc., a joint venture biotechnology company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. announced today that it has initiated IND-enabling development of a novel compound, PSN0041, for the treatment of depression.
Read More >

Psylin: Peptides for the CNS

April 20, 2009 — While the vast majority of marketed antidepressants are oral small molecules, Psylin Neurosciences Inc. thinks its injectable product will be competitive based on an improved safety profile and added benefits in weight loss and cognition. On Monday this week, the company was to announce its first IND candidate, a peptide hormone that will be developed for treatment-resistant depression.
Download PDF >

PsychoGenics Inc. Announces The Launch Of Psylin Neurosciences, Inc. In Partnership With Amylin Pharmaceuticals, Inc.

January 30, 2007 — PsychoGenics Inc. announced today that together with Amylin Pharmaceuticals, Inc. they have formed Psylin Neurosciences, Inc. (Psylin), a new company that will focus on the discovery and development of peptide hormones for treatment of psychiatric disorders. PsychoGenics and Amylin participated equally in a Series A financing of Psylin anticipated to fund the company for approximately the next two years.
Read More >